Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Q3 2022 Earnings Presentation
18 slides from Myriad Genetics's earnings presentation, Nov 1, 2022
Slide 1: Myriad Genetics Third Quarter 2022 Earnings
Myriad Genetics Third Quarter 2022 Earnings November 1, 2022
Slide 2: Forward looking statements
Forward looking statements Some of the information These statements are based on management’s current expectations and the actual presented here today may events or results may differ materially and adversely from these expectations. We contain projections or refer you to the documents the Company f
Slide 3: Who we are, what we do, and why it matters
Who we are, what we do, and why it matters Illuminating the path to better health through genetic insights. Our purpose-led Mission We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. Our Vision As a leader in genetic testing and precision
Slide 4: Third quarter operating and financial highlights
Third quarter operating and financial highlights Core Volume HCT & GeneSight Pricing Stable with Tuck In Gross Margin Growth Volume Growth Visibility into Acquisition Stable YTD Continues Ramping Medicare Rate Completed +12% +4% MolDx program assigned the MyRisk +70% Acquired Gateway Genomics, a per
Slide 5: Building on strong Women's Health franchise
Building on strong Women’s Health franchise Transaction rationale • Alignment with core Women’s Health; Moving closer to the customer Personal genomics company with the mission to • Strong brand reputation; 76-point Net develop leading-edge genetic tests that give families a Promoter Score (NPS) new
Slide 6: Active pipeline to drive long-term accelerating growth
Active pipeline to drive long-term accelerating growth Women’s Oncology Oncology Health FirstGene Precise Liquid Precise MRD 4-in-1 prenatal screening Robust tumor profiling & therapy selection Minimal residual disease monitoring What is It? Single integrated assay What is It? Comprehensive genomic
Slide 7: Nicole Lambert, Chief Operating Officer
Nicole Lambert, Chief Operating Officer
Slide 8: Mental Health: Setting another record
Mental Health: Setting another record Using genetic insights Quarterly highlights to help physicians • Surpassed 2 million patients understand how genetic worldwide with GeneSight to date o Over two years of sequential alterations impact quarterly volume growth patient response to Mental • Achieved
Slide 9: Women's Health: Volume growth in hereditary cancer testing
Women’s Health: Volume growth in hereditary cancer testing Leading health and Quarterly highlights wellness with best-in- • Women’s Health hereditary cancer class genetic insights testing volumes returned to growth in the third quarter for women of all o Momentum going into the fourth ancestries, as
Slide 10: Oncology: Build on strong Hereditary Cancer Position & FDA approved companion diagnostic tests
Oncology: Build on strong Hereditary Cancer Position & FDA approved companion diagnostic tests Clarifying cancer Quarterly highlights treatment with genetic • Precise Tumor volume levels and insights and companion adoption rate continue to grow o Strong attachment rate to other diagnostic tests that
Slide 11: Bryan Riggsbee, Chief Financial Officer
Bryan Riggsbee, Chief Financial Officer
Slide 12: Organic revenue growth driven by GeneSight
Organic revenue growth driven by GeneSight $500 Revenue Notes: 5% • 2% headwind to growth YTD from $7.1 million impact of currency translation (YTD22) and a $4 million non- recurring milestone payment in third quarter 2021 $ in millions • Revenue growth driven by: $500.3 o HCT volumes +4% year-over-
Slide 13: Revenue progression reflects normal seasonal trends
Revenue progression reflects normal seasonal trends; 2Q22 – 4Q22E $180 $179.3 Takeaways: • Third quarter reflects normal seasonality offset by growth • Headwind to third quarter revenue Revenue ($ in millions) ~5% $168 - $172 compared to previous quarter includes: o ~$17.0 million change of estimate
Slide 14: Adjusted operating expense trends stable in difficult inflationary environment
Adjusted operating expense trends stable in difficult inflationary environment and reflect growth initiatives $300 ~$260.0 6% • Company continues to manage $245.3 growth in Adjusted OpEx prudently. Adj OpEx Increase driven by: 1H22A vs 2H22E o Strategic investments in $133.0 4Q22E Mental technology
Slide 15: Updated fiscal year 2022 financial guidance
Updated fiscal year 2022 financial guidance ($ in millions, except per share amounts) Revenue Takeaways: Updated $668 - $672 • $15 million reduction in full year Previous $670 - $700 revenue guidance driven primarily Change Decrease midpoint $15 by headwinds from change of Gross Margin % estimates (
Slide 16: Investment case: strengths and strategic advantages
Investment case: strengths and strategic advantages Significant market growth in Leader in genetic testing and precision medicine focused business areas Best-in-class • Growing test volumes product quality • Price stability & visibility Strong scalable commercial • Disciplined investment & cost engi
Slide 17: Myriad Genetics Health. Illuminated.
Myriad genetics Health. Illuminated.
Slide 18: Thank you
Thank you ©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com